Clinical trials: Cholangiocarcinoma, Extrahepatic
Jaundice, Obstructive, Klatskin Tumor
Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice
The purpose of this study is to evaluate the safety and effectiveness of different methods of preoperative biliary drainage in patients with extrahepatic bile duct neoplasms with obstructive jaundice (hilar cholangiocarcinoma…
- Trial name
- NCT03527875
- Testing
- PTBD group, ENBD group, EBS group
- Volunteers
- 564 people
- Sponsor
- Shanghai Zhongshan Hospital
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma
- Trial name
- NCT01093222
- Testing
- Erlotinib Hydrochloride, Sorafenib Tosylate
- Where
- 141 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for…
- Trial name
- NCT03929666
- Testing
- ZW25 (Zanidatamab), Capecitabine, Cisplatin
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 74 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
This study is an open-label, phase II study of irinotecan liposome injection in patients with advanced biliary tract cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan…
- Conditions
- Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT05009953
- Testing
- Irinotecan Liposome Injection, SG001, Fluorouracil
- Where
- China
- Volunteers
- 17 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Extrahepatic Cholangiocarcinoma
An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma
This is an open-label, single-arm, multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with TACE in the treatment of extrahepatic cholangiocarcinoma.
- Trial name
- NCT05448183
- Testing
- Toripalimab, Gemcitabine,Oxaliplatin
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Xuhua Duan
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and…
- Trial name
- NCT00919061
- Testing
- Gemcitabine, Cisplatin, Sorafenib
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Extrahepatic Cholangiocarcinoma, Malignant Biliary Obstruction
Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma
With the development of endoscopic technology, endoscopic retrograde cholangiopancreatography (ERCP) has been widely used in the diagnosis and treatment of extrahepatic cholangiocarcinoma.In patients with extrahepatic…
- Trial name
- NCT05233293
- Testing
- Spyglass + RFA, Cytobrush + RFA
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First People's Hospital of Hangzhou
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery
RATIONALE: Biliary stenting is the placement of a tube in the bile ducts to keep a blocked area open. Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells.
- Trial name
- Photostent-02 (NCT00513539)
- Testing
- porfimer sodium, biliary stenting
- Where
- 4 sites in United Kingdom
- Volunteers
- 92 people
- Sponsor
- University College, London
Esophageal Cancer, Extrahepatic Bile Duct Cancer
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT00021047
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- 3 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Cancer, Depression
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
RATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer.
- Conditions
- Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00387348
- Testing
- escitalopram oxalate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Anal Cancer, Colorectal Cancer
Interleukin-12 in Treating Patients With Cancer in the Abdomen
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00003046
- Testing
- Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Biliary Tract Cancer, Cholangiocarcinoma
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
This study is going to test the ability to successfully obtain results from certain personalized tests for patients with biliary tract cancers that are able to be surgically removed.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04561453
- Testing
- Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Washington
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003296
- Testing
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brown University
Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
This phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating…
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma
- Trial name
- NCT07765433
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 336 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
This phase II trial studies how well selumetinib and Akt inhibitor MK-2206 work in treating patients with refractory or advanced gallbladder or bile duct cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
- Trial name
- NCT01859182
- Testing
- selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis
- Sponsor
- National Cancer Institute (NCI)